Q-omics provides the consensus-scored TMEM125 profile across patient tissues and cancer cell-line models. TMEM125 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM125 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, TMEM125 RNA expression shows 21,858 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where TMEM125 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM125 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM125 survival associations across molecular data types. TMEM125 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM125 RNA expression–survival associations across cancer types. High TMEM125 expression shows unfavorable associations in LUSC, but favorable associations in KIRC, KIRP, LUAD, SCLC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM125 RNA expression.
This table summarizes TMEM125 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM125. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM125 shows lower tumor expression in HNSC, KICH, KIRC, LUSC, KIRP and LUAD. The HNSC box plot shows higher TMEM125 RNA expression in normal versus tumor tissue (log2 FC = −1.287, t-test p < 0.001).
This table shows molecular features associated with TMEM125 in patient tissues and cancer cell lines. In patient samples, TMEM125 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM125 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
